Antiemetics

Chairman of New You, Inc. CBD Acquisition Subsidiary ST Brands to Speak on Panel Entitled "The Companies Driving International Market Growth" at the Benzinga Cannabis Capital Conference, Thursday, June 3

Retrieved on: 
Wednesday, June 2, 2021
Drugs, Health sciences, Health care, Antiemetics, Analgesics, Anticonvulsants, Cannabidiol, Cannabinoids, Medical cannabis, Brand, CBD, Hemp

New You, Inc. (OTCQB: NWYU) wholly-owned subsidiary ST Brands Corp is a capital and growth platform for high potential consumer cannabidiol (CBD) companies that create, develop, market, and sell unique and proprietary products to various segments of the global consumer market.

Key Points: 
  • New You, Inc. (OTCQB: NWYU) wholly-owned subsidiary ST Brands Corp is a capital and growth platform for high potential consumer cannabidiol (CBD) companies that create, develop, market, and sell unique and proprietary products to various segments of the global consumer market.
  • ST Brands applies financial, operational, branding resource infrastructure to deliver turnkey business services and achieve economies of scale in capital, sourcing, production, packaging, and sales.
  • ST Brands acquires scalable cannabis companies with the potential to become sector leaders in the legal cannabis market.
  • The conference will feature an interactive forum of live presentations from top CEOs, investors, and leaders in the cannabis space.

Evoke Pharma Announces Issuance of a New U.S. Patent Covering Methods of Use for Gimoti®

Retrieved on: 
Wednesday, June 2, 2021
Medical specialties, Gastroenterology, Digestive diseases, Antiemetics, Chloroarenes, Prolactin releasers, 5-HT3 antagonists, Gastroparesis, Metoclopramide, Food and Drug Administration, United States patent law

Gimoti is Evokes nasal spray product for the relief of symptoms in acute and recurrent diabetic gastroparesis.

Key Points: 
  • Gimoti is Evokes nasal spray product for the relief of symptoms in acute and recurrent diabetic gastroparesis.
  • The U.S. Food and Drug Administration (FDA) approved the New Drug Application for Gimoti in June 2020.
  • We are pleased to announce the issuance of this new U.S. patent which further validates that Gimoti is innovative and novel.
  • The issuance of this patent strengthens the intellectual property protection for Gimoti and supports our commercial efforts to make Gimoti the treatment of choice in the gastroparesis market.

Grapefruit USA, Inc. Issues Update Concerning the Company’s Progress Through the First Five Months of 2021

Retrieved on: 
Tuesday, June 1, 2021
Appetite stimulants, Entheogens, Euphoriants, Antiemetics, Medicinal plants, Branches of biology, Drugs, Psychoactive drugs, Hemp, Tetrahydrocannabinol, Cannabis, Medical cannabis

As a result, Grapefruit now manufactures and markets the worlds first and only maximally bioavailable, time release delivered THC-free, hemp derived CBD topical product.

Key Points: 
  • As a result, Grapefruit now manufactures and markets the worlds first and only maximally bioavailable, time release delivered THC-free, hemp derived CBD topical product.
  • These TV platforms have the potential to reach over 540 million homes in the U.S. and international markets.
  • * On March 1, 2021, the Company announced it had been approached by a Canadian cannabis company to enter into discussions concerning a potential acquisition transaction.
  • We remain committed to providing our shareholders and the public with material information concerning the Company as soon as possible.

Evoke Pharma and EVERSANA Launch Social Media Campaign for Gimoti® Nasal Spray

Retrieved on: 
Thursday, May 27, 2021
Medical specialties, Gastroenterology, Clinical medicine, Chloroarenes, Antiemetics, Prolactin releasers, Dosage forms, Gastroparesis, Metoclopramide, Forward-looking statement, Nasal spray

You report side effects related to Evoke Pharma products by calling 1-833-4-GIMOTI (1-833-444-6684) or emailing [email protected].

Key Points: 
  • You report side effects related to Evoke Pharma products by calling 1-833-4-GIMOTI (1-833-444-6684) or emailing [email protected].
  • The Company developed GIMOTI, a nasal spray formulation of metoclopramide, for the relief of symptoms associated with acute and recurrent diabetic gastroparesis in adults.
  • Evoke cautions you that statements included in this press release that are not a description of historical facts are forward-looking statements.
  • These forward-looking statements include statements regarding Evokes expectations on the social media marketing campaign.

Zynerba Pharmaceuticals to Present at the Jefferies Virtual Healthcare Conference

Retrieved on: 
Wednesday, May 26, 2021
Drugs, Antiemetics, Entheogens, Tetrahydrocannabinol, Cannabinoid, Neurochemistry, Psychoactive drugs

DEVON, Pa., May 26, 2021 (GLOBE NEWSWIRE) -- Zynerba Pharmaceuticals, Inc. (Nasdaq: ZYNE), the leader in innovative pharmaceutically-produced transdermal cannabinoid therapies for rare and near-rare neuropsychiatric disorders, today announced that Armando Anido, Chairman and Chief Executive Officer of Zynerba, will present a company overview during the Jefferies Virtual Healthcare Conference on Thursday, June 3, 2021 at 4:30 p.m.

Key Points: 
  • DEVON, Pa., May 26, 2021 (GLOBE NEWSWIRE) -- Zynerba Pharmaceuticals, Inc. (Nasdaq: ZYNE), the leader in innovative pharmaceutically-produced transdermal cannabinoid therapies for rare and near-rare neuropsychiatric disorders, today announced that Armando Anido, Chairman and Chief Executive Officer of Zynerba, will present a company overview during the Jefferies Virtual Healthcare Conference on Thursday, June 3, 2021 at 4:30 p.m.
  • Investors interested in arranging a virtual meeting with the Companys management during the conference should contact the Jefferies conference coordinator.
  • A webcast of the presentation will be available under the Events & Webcasts tab of the Investors section of the Zynerba website at www.zynerba.com .
  • Zynerba Pharmaceuticals is the leader in innovative pharmaceutically-produced transdermal cannabinoid therapies for rare and near-rare neuropsychiatric disorders.

Leafreport Releases Findings From Pet CBD Report Showing 56 Percent of Products Have Inaccurate Label Claims

Retrieved on: 
Wednesday, May 19, 2021
Euphoriants, Cannabis, Antiemetics, Entheogens, Drugs, Tetrahydrocannabinol, Psychoactive drugs, Neurochemistry

The rest were off by anywhere from 10.2% to 98.5% from the label.

Key Points: 
  • The rest were off by anywhere from 10.2% to 98.5% from the label.
  • Notably, 56% (31) of the tested products had CBD levels that differed from the label by more than the acceptable 10% variance.
  • Of the total tested products, 22 had no THC, despite companies claiming they contained full-spectrum CBD.
  • One lingering problem is that many products don\xe2\x80\x99t contain the correct amount of CBD,\xe2\x80\x9d said Lital Shafir, the head of product at Leafreport.

NuSachi, Inc. Joins Efforts to Prove THC Safety in Food Products

Retrieved on: 
Tuesday, May 18, 2021
Appetite stimulants, Entheogens, Euphoriants, Drugs, Psychoactive drugs, Branches of biology, Antiemetics, Cannabis, Tetrahydrocannabinol, Hemp

"EIHA\'s work is good for the industry and the forthcoming insights are sorely needed to help shape public policy and inform regulatory bodies everywhere to make more responsible decisions around THC thresholds for products derived from the plant.

Key Points: 
  • "EIHA\'s work is good for the industry and the forthcoming insights are sorely needed to help shape public policy and inform regulatory bodies everywhere to make more responsible decisions around THC thresholds for products derived from the plant.
  • "\nThe EIHA is investing nearly US $2 million dollars in its THC study on human beings with trials already underway and preliminary results expected this summer.
  • NuSachi offers expertise and services spanning genetics, plant material, extracts, custom formulations, white labeling, and comprehensive turnkey solutions.
  • NuSachi is based in Nashville, Tenn. and can be found online at nusachi.com or via social media @nusachihemp .\n'

NEXT SUPER STOCKS on The Move: Tetra Bio-Pharma, Relay Medical, Victory Square Technologies, and Red Light Holland

Retrieved on: 
Friday, May 7, 2021
Branches of biology, Clinical medicine, Medicine, Appetite stimulants, Antiemetics, Entheogens, Euphoriants, Aromatase inhibitors, Tetrahydrocannabinol, Vomiting, Nausea, Bitly

REDUVO is a synthetic THC-based soft gel capsule indicated in severe nausea and vomiting associated with cancer chemotherapy.

Key Points: 
  • REDUVO is a synthetic THC-based soft gel capsule indicated in severe nausea and vomiting associated with cancer chemotherapy.
  • A highlight of the presentation was a video demo of the company\xe2\x80\x99s rapid testing and tracking platform for infectious diseases, including COVID-19.
  • iMicrodose Packs powered by Red Light Holland are now available in 144% more locations than previously announced.
  • Full disclaimer, and relevant SEC 17B disclosures here: http://bit.ly/39kkE7K\nAbout Wall Street Reporter\xe2\x80\x99s Next Super Stock conference:\nWall Street Reporter\'s NEXT SUPER STOCK Live!

Avicanna Makes RHO Phyto™ Medical Cannabis Products Available In Canadian Hospital Pharmacies Through Agreement with Sunnybrook Hospital

Retrieved on: 
Thursday, May 6, 2021
Entheogens, Euphoriants, Psychoactive drugs, Medicinal plants, Appetite stimulants, Drugs, Antiemetics, Branches of biology, Tetrahydrocannabinol, Cannabis, Medical cannabis, Effects of cannabis

This first of its kind collaboration will focus on increasing healthcare provider and patient education on medical cannabis products and provide patients with a one stop process for accessing plant-based cannabis for medical use, in coordination with their hospital healthcare team.

Key Points: 
  • This first of its kind collaboration will focus on increasing healthcare provider and patient education on medical cannabis products and provide patients with a one stop process for accessing plant-based cannabis for medical use, in coordination with their hospital healthcare team.
  • Avicanna and Sunnybrook Hospital aim to establish a gold standard of care for cannabinoid-based medicine by providing support and educating and training physicians, pharmacists and patients on the formulary of the RHO Phyto products.
  • The RHO Phyto product line consists of oral, sublingual, and topical delivery systems offered in a range of CBD only and CBD-THC ratios.
  • All RHO Phyto formulations are designed to maintain the stability of the cannabinoids, and provide accurate dosing.

POSaBIT FY 2020 Revenue Increases 127% to $7.8 Million, Transactional Sales Grow 155%

Retrieved on: 
Thursday, May 6, 2021
Professional services, Retail, Technology, Other Technology, Tobacco, Finance, Hardware, Health sciences, Antiemetics, Antioxidants, Medical cannabis, Pharmacognosy, Pharmaceutical sciences, Branches of biology

Although we believe that the assumptions underlying these statements are reasonable, they may prove to be incorrect.

Key Points: 
  • Although we believe that the assumptions underlying these statements are reasonable, they may prove to be incorrect.
  • POSaBIT specializes in resolving pain points for complex, high-risk, emerging industries like cannabis with an all-in-one solution that is compliant, user-friendly and utilizes top-of-the-line hardware.
  • POSaBIT\xe2\x80\x99s unique solution provides a safer and transparent environment for merchants while creating a better overall experience for the consumer.
  • For additional information, visit: www.posabit.com .\nView source version on businesswire.com: https://www.businesswire.com/news/home/20210506005233/en/\n'